192 related articles for article (PubMed ID: 21713004)
41. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.
Riederer K; Shemes S; Chase P; Musta A; Mar A; Khatib R
J Clin Microbiol; 2011 Jun; 49(6):2147-50. PubMed ID: 21490190
[TBL] [Abstract][Full Text] [Related]
42. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates.
Campanile F; Borbone S; Perez M; Bongiorno D; Cafiso V; Bertuccio T; Purrello S; Nicolosi D; Scuderi C; Stefani S
Int J Antimicrob Agents; 2010 Nov; 36(5):415-9. PubMed ID: 20727722
[TBL] [Abstract][Full Text] [Related]
43. Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus.
Harigaya Y; Ngo D; Lesse AJ; Huang V; Tsuji BT
BMC Infect Dis; 2011 Oct; 11():287. PubMed ID: 22026752
[TBL] [Abstract][Full Text] [Related]
44. Molecular and Clinical Features of Heterogeneous Vancomycin-Intermediate
Sreejisha M; Shenoy MS; Shenoy MS; Dhanashree B; Chakrapani M; Bhat KG
Sultan Qaboos Univ Med J; 2023 Nov; 23(4):447-454. PubMed ID: 38090245
[TBL] [Abstract][Full Text] [Related]
45. Investigation of heteroresistant vancomycin intermediate Staphylococcus aureus among MRSA isolates.
Gazel D; Erinmez M; Büyüktaş Manay A; Zer Y
J Infect Dev Ctries; 2021 Jan; 15(1):89-94. PubMed ID: 33571150
[TBL] [Abstract][Full Text] [Related]
46. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.
Casapao AM; Leonard SN; Davis SL; Lodise TP; Patel N; Goff DA; LaPlante KL; Potoski BA; Rybak MJ
Antimicrob Agents Chemother; 2013 Sep; 57(9):4252-4259. PubMed ID: 23796929
[TBL] [Abstract][Full Text] [Related]
47. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method.
Wang JL; Wang JT; Sheng WH; Chen YC; Chang SC
BMC Infect Dis; 2010 Jun; 10():159. PubMed ID: 20529302
[TBL] [Abstract][Full Text] [Related]
48. Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.
Bakthavatchalam YD; Babu P; Munusamy E; Dwarakanathan HT; Rupali P; Zervos M; John Victor P; Veeraraghavan B
PLoS One; 2019; 14(12):e0227009. PubMed ID: 31887179
[TBL] [Abstract][Full Text] [Related]
49. [Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years].
Kızılarslanoğlu MC; Sancak B; Yağcı S; Hasçelik G; Unal S
Mikrobiyol Bul; 2013 Apr; 47(2):199-210. PubMed ID: 23621720
[TBL] [Abstract][Full Text] [Related]
50. Vancomycin MIC and agr dysfunction in invasive MRSA infections in southern Brazil.
Rossato AM; Primon-Barros M; Dias CAG; d'Azevedo PA
Braz J Microbiol; 2020 Dec; 51(4):1819-1823. PubMed ID: 33074551
[TBL] [Abstract][Full Text] [Related]
51. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.
Castro BE; Berrio M; Vargas ML; Carvajal LP; Millan LV; Rios R; Hernandez AK; Rincon S; Cubides P; Forero E; Dinh A; Seas C; Munita JM; Arias CA; Reyes J; Diaz L
J Antimicrob Chemother; 2020 Sep; 75(9):2424-2431. PubMed ID: 32562543
[TBL] [Abstract][Full Text] [Related]
52. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
Joo J; Yamaki J; Lou M; Hshieh S; Chu T; Shriner KA; Wong-Beringer A
Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
[TBL] [Abstract][Full Text] [Related]
53. Decreasing prevalence of isolates with vancomycin heteroresistance and vancomycin minimum inhibitory concentrations ≥2 mg/L in methicillin-resistant Staphylococcus aureus over 11 years: potential impact of vancomycin treatment guidelines.
Khatib R; Sharma M; Johnson LB; Riederer K; Shemes S; Szpunar S
Diagn Microbiol Infect Dis; 2015 Jul; 82(3):245-8. PubMed ID: 25935628
[TBL] [Abstract][Full Text] [Related]
54. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
[TBL] [Abstract][Full Text] [Related]
55. Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China.
Liu C; Chen ZJ; Sun Z; Feng X; Zou M; Cao W; Wang S; Zeng J; Wang Y; Sun M
J Microbiol Immunol Infect; 2015 Oct; 48(5):490-6. PubMed ID: 24767415
[TBL] [Abstract][Full Text] [Related]
56. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital.
Di Gregorio S; Perazzi B; Ordoñez AM; De Gregorio S; Foccoli M; Lasala MB; García S; Vay C; Famiglietti A; Mollerach M
Microb Drug Resist; 2015 Feb; 21(1):25-34. PubMed ID: 25535825
[TBL] [Abstract][Full Text] [Related]
57. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
[TBL] [Abstract][Full Text] [Related]
58. Multiomics characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolates with heterogeneous intermediate resistance to vancomycin (hVISA) in Latin America.
Castro BE; Rios R; Carvajal LP; Vargas ML; Cala MP; León L; Hanson B; Dinh AQ; Ortega-Recalde O; Seas C; Munita JM; Arias CA; Rincon S; Reyes J; Diaz L
J Antimicrob Chemother; 2022 Dec; 78(1):122-132. PubMed ID: 36322484
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
60. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
Tran N; Rybak MJ
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
